Bioceros Revenue and Competitors

Claim your profile

Utrecht, Netherlands

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Bioceros's estimated annual revenue is currently $8.5M per year.(i)
  • Bioceros's estimated revenue per employee is $155,000

Employee Data

  • Bioceros has 55 Employees.(i)
  • Bioceros grew their employee count by -7% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$22.5M145-2%N/AN/A
#2
$8.5M55-7%N/AN/A
#3
$8.7M56-5%N/AN/A
#4
$6.7M43-2%N/AN/A
#5
$15.7M101-19%N/AN/A
#6
$7M450%N/AN/A
#7
$2.3M1515%N/AN/A
#8
$2.8M1850%N/AN/A
#9
$7.4M480%N/AN/A
#10
$7.9M51240%N/AN/A

Bioceros is one of Europe's premier providers of GMP-ready protein producing cell lines that operates from within the PolPharma Group. Bioceros has developed a proprietary animal-component free, suspension CHO platform (named CHOBC®) that is used for stable Cell Line Development. All the Cell Line Development work that we perform is Quality Controlled. We have generated cell lines producing proteins ranging from blood proteins and monoclonal antibodies to fusion proteins and enzymes. For monoclonal antibodies, our services start based on customers wishes, either with cDNA sequences to be expressed or by generation of antibodies in rodents, followed by cloning of the sequences from selected hybridomas. Further services include immunoassays, with a particular emphasis on cell based assays, as well as down-stream process development and full analytical analysis (i.e. glycan structures, charge variants and many other relevant quality attributes). Additionally, our CHOBC® platform has enabled us to generate high-producing biosimilar expressing cell lines that have been extensively analyzed to optimize the process conditions and thus yield highly similar antibodies when compared to the originators. These cell lines are available for out-licensing or co-development in various stages of development. The people at Bioceros strongly believe that true and close collaboration speeds up selection and development of clients most viable drug candidates. Therefore, the programs are designed in a flexible way, and scientists and staff involved in the programs are easily approachable.

keywords:N/A

N/A

Total Funding

55

Number of Employees

$8.5M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Bioceros News

2019-09-08 - Cell Line Development Market Competitive Landscape ...

... Epistem Holdings, Catalent, Bioceros, Abzena, Promocell, and Cyagen, are key players operating in the global cell line development market.

2019-09-03 - Cell Line Development Market Recent Trends, Development,Growth & Forecast 2018 – 2028

... Vista Biologics, EuBiologics, Paragon Bioservices, Cobra Biologics, Patheon, Samsung Biologics, Epistem Holdings, Catalent, Bioceros, Abzena, Promocell, ...

2019-09-03 - Four Key Reasons to Attend SMi's 2019 Biosimilars Conference

Using SPOT and SLIM Technology and Upstream Process Modulation to Reduce Cost of Goods of Biosimilars' by Louis Boon, CSO, Bioceros ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.2M5520%N/A
#2
$8.7M56-5%N/A
#3
$16.6M57-10%N/A
#4
$16.9M5832%N/A
#5
$14.1M582%N/A